Goldman Sachs
AARD

Goldman Sachs’s Aardvark Therapeutics AARD Stock Holding History

Goldman Sachs’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.5K Sell
12,241
-7,163
-37% -$33.5K ﹤0.01% 6380
2026
Q1 		$73.2K Sell
19,404
-33,945
-64% -$352K ﹤0.01% 6251
2025
Q4 		$700K Buy
53,349
+34,422
+182% +$430K ﹤0.01% 5384
2025
Q3 		$252K Buy
18,927
+332
+2% +$3.74K ﹤0.01% 5850
2025
Q2 		$251K Sell
18,595
-1,716
-8% -$17.7K ﹤0.01% 5544
2025
Q1 		$153K Buy
+20,311
New +$228K ﹤0.01% 5698

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Goldman Sachs's AARD Position: Q2 2026 in Review

Goldman Sachs reduced its Aardvark Therapeutics (AARD) stake by 37% in Q2 2026, selling an estimated $33.5K and leaving 12,241 shares worth $70.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6380.

Goldman Sachs first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $700K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Goldman Sachs held 12,241 shares of Aardvark Therapeutics worth $70.5K as of Q2 2026.
  • Goldman Sachs sold 7,163 Aardvark Therapeutics shares in Q2 2026, an estimated $33.5K.
  • Aardvark Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6380 holding.
  • Goldman Sachs first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Goldman Sachs's Aardvark Therapeutics position peaked at $700K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.